Rigel…expects VEPPANU to be commercially available in the United States for the treatment of second line-plus (2L+) ER+/HER2-, ESR1-mutated mBC in mid-August 2026

Veppanu (vepdegestrant) - Rigel Pharmaceuticals

Aug 4, 2026